VAC4EU: a pan-European research network for collaborative post-authorization vaccine safety and benefit monitoring

Gianmarco Di Mauro^{1,2}*, Rosa Gini^{1,4}*, Patrick Mahy¹*, Eva Molero^{1,2}*, Miriam Sturkenboom^{1,3}*, Daniel Weibel^{1,3}*

- 1 Vaccine monitoring Collaboration for Europe (VAC4EU), Bruxelles, Belgium
- 2 Teamit Institute, Barcelona, Spain
- 3 University Medical Center Utrecht, the Netherlands
- 4 Agenzia regionale di sanità della Toscana, Florence, Italy
- Equal contribution of the authors, alphabetical order.

Background

VAC4EU (Vaccine monitoring Collaboration for Europe) is a not-for profit international association with 25 member organizations specialised in the collaborative generation of real-world evidence on coverage, safety, and efficacy of vaccines in Europe. VAC4EU was established as a result of the IMI-ADVANCE project with the aim to enable, coordinate and accelerate the creation of the best evidence at European level on vaccine effects. In the past two years, VAC4EU has proven preparedness and efficiency in designing post-authorization monitoring for COVID-19 vaccines responding to the requests of both the European Medicines Agency (EMA) and vaccine manufacturers.

Objectives

To describe the VAC4EU organization, data, tools and the accomplishments made towards the generation of real-world evidence on vaccine benefit-risk evaluation.

Results

Since its creation in October 2019, VAC4EU has established a large research network composed of 25 institutions from 9 European countries (BE, DE, DK, FR, IT, NL, NO, ES, UK) providing access to 15 health care data sources covering more than 150 million European citizens [FIGURE 1] [TABLE 1]

VAC4EU has implemented a research infrastructure including a catalogue, a codemapper tool, a sharepoint, Github, digital research environment (DRE), a phenotype library of more than 100 variables with definitions and a Zenodo community to facilitate collaboration, transparency, and federated data analysis *[FIGURE 2]*. VAC4EU has adopted the ConcePTION common data model as a basis for the structural harmonization of electronic health data, but it also allows for primary data collection

VAC4EU has consolidated its governance structure for implementation of pharmacovigilance studies on vaccines *[FIGURE 3]* and successfully participated in four public tenders regarding vaccines safety and effectiveness launched by the European Medicines Agency (EMA) ^{1, 2, 3, 4} as well as four required post-authorization safety studies on COVID-19 vaccines sponsored by vaccine manufacturers ^{5, 6, 7, 8}, and other studies promoted by the Global Vaccine Data Network *[FIGURE 4]*. All protocols developed within VAC4EU are registered in the EU PAS register, and results are published in the open science VAC4EU Zenodo community.

Conclusions

We know already from the H1N1 pandemic that collaboration is needed to study vaccine effects. This collaboration was designed and tested in the IMI-ADVANCE project and implemented in VAC4EU. VAC4EU has demonstrated readiness of its research framework making a key difference in COVID-19 vaccine monitoring in Europe. Research and public health organizations can join the initiative.

Declaration of interest

The authors and their departments conduct research for government, public, and private organizations, including pharmaceutical companies, according to the ENCePP code of conduct.



INSTITUTION		DESCRIPTION
Agenzia Regionale di Sanità (ARS) Toscana.	0	Regional public health agency. Expertise in vaccine studies and COVID-19 studies, access to administrative health care data (mortality, hospital admissions, ER access, drug claims & vaccines, health care assistance), in Tuscany region (3.5 million residents). https://www.ars.toscana.it
Bordeaux PharmacoEpi (BPE)	0	A research platform of the Université de Bordeaux specialized in real world evidence with extensive experience in conducting fields studies and studies based on the French national healthcare database (SNDS). https://www.bordeauxpharmacoepi.eu
Drug Safety Research Unit (DSRU)	4 2 3 2 3 3 3 3 3 3 3 3 3 3	The DSRU is a private research organization in the UK which monitors the safety of medicines and vaccines and uses UK databases. https://www.dsru.org/
FISABIO		The Foundation for the Promotion of Health and Biomedical Research of Valencia Region has access to regional health and vaccine data. http://fisabio.san.gva.es/
IDIAP-Jordi Gol		A public primary health care research organization. Home to the SIDIAP database, Information System for Research in Primary Care, electronic health data. https://www.idiapjgol.org/index.php/en/
Instituto Aragonés de Ciencias de la Salud (IACS)		Providing access to the EpiChron Cohort Study of all the inhabitants of Aragón comprising, about 2M subjects with historic data, and 1.3 M active population subjects.
Julius Clinical Research BV		Science contract research organization that manages global clinical drug trials & real-world evidence studies. https://www.juliusclinical.com
LAREB		Netherlands national pharmacovigilance center, ample expertise in regular pharmacovigilance and intensive monitoring of influenza and pneumococcal vaccines. www.lareb.nl
Lazio Regional Health Service	•	Regional public health agency. Expertise in vaccine studies and COVID-19 studies, access to administrative health care data (mortality, hospital admissions, ER access, drug claims & vaccines, health care assistance), in Lazio region (6 million residents). https://www.deplazio.net/en
Leibniz Institute for Prevention Research and Epidemiology – BIPS	•	Home to the German Pharmacoepidemiologic Research Database (GePaRD), claims data from statutory health insurance providers and currently includes information on about 25 million persons. https://www.bips-institut.de
Penta foundation	0	A private non-for-profit foundation hosting a global pediatric research network, which has coordinated hundreds of multisite clinical trials and cohort studies in infectious diseases in the past 30 years. https://penta-id.org/

Table 1: VAC4EU members



Figure 1: VAC4EU data sources and data access providers per country







Figure 2: VAC4EU research infrastructure



References

- 1. Willame, C, Dodd, C, Gini, R, Durán, CE, Thomsen, RM, Wang, L, Gedebjerg, A, Kahlert, J, Ehrenstein, V, Bartolini, C, Droz, C, Moore, N, Haug, U, Schink, T, Diez-Domingo, J, Mira-Iglesias, A, Vergara-Hernández, C, Carreras, JJ, Villalobos, F, ... Sturkenboom, MCJM. (2021). Background rates of Adverse Events of Special Interest for monitoring COVID-19 vaccines (2.0). Zenodo. https://doi.org/10.5281/zenodo.5255870
- 2. An Observational Post-Authorization Safety Study to Assess the Safety of Ad26.COV2.S Using European Healthcare Data through VAC4EU (COVID-19) https://www.encepp.eu/encepp/viewResource.htm?id=46985
- 3. Cohort monitoring of Adverse Events of Special Interest and COVID-19 diagnoses prior to and after COVID-19 vaccination https://www.encepp.eu/encepp/viewResource.htm?id=44372
- 4. Rapid Safety Assessment of SARS-CoV-2 vaccines in EU Member States using electronic health care datasources https://www.encepp.eu/encepp/viewResource.htm?id=42637
- 5. Post Conditional Approval Active Surveillance Study Among Individuals in Europe Receiving the Pfizer-BioNTech
- Coronavirus Disease 2019 (COVID-19) Vaccine https://www.encepp.eu/encepp/viewResource.htm?id=46939
 6. A post-authorisation/post-marketing observational study to evaluate the association between exposure to AZD1222 and safety concerns using existing secondary health data sources (COVID-19)

 https://www.encepp.eu/encepp/viewResource.htm?id=47086
- 7. Monitoring safety of Spikevax in pregnancy: an observational study using routinely collected health data in five European countries (COVID-19) https://www.encepp.eu/encepp/viewResource.htm?id=45467
- 8. Post-Authorization Active Surveillance Safety Study Using Secondary Data to Monitor Real-World Safety of Spikevax in Europe (COVID-19) https://www.encepp.eu/encepp/viewResource.htm?id=45470